Cognition Therapeutics, Inc. announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will fund preclinical studies of two sigma-2 (s-2) receptor modulators in animal models of Parkinson's disease that will be led by Cognition Therapeutics' VP of research, Mary E. Hamby, Ph.D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | +1.04% | +5.98% | +5.41% |
Apr. 12 | Transcript : Cognition Therapeutics, Inc. - Special Call | |
Mar. 26 | Transcript : Cognition Therapeutics, Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.41% | 75.27M | |
-2.35% | 103B | |
+0.92% | 95.71B | |
+2.01% | 22.02B | |
-16.78% | 20.9B | |
-9.07% | 17.85B | |
-42.83% | 16.21B | |
-14.51% | 15.52B | |
+3.73% | 13.86B | |
+33.34% | 12.04B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson's Disease